HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
April 27, 2021
-
ACADEMIA New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
-
REGULATORY Olumiant Snags Japan Approval for COVID-19
April 23, 2021
-
BUSINESS Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
-
BUSINESS Supply Delays Likely for 160 Nichi-Iko Products despite Biz Suspension Lifted
April 22, 2021
-
REGULATORY Olumiant Now in Line for Japan Nod for COVID-19 Pneumonia
April 22, 2021
-
BUSINESS MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
-
ORGANIZATION EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
-
BUSINESS New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
April 20, 2021
-
REGULATORY MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
April 19, 2021
-
ORGANIZATION Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
-
REGULATORY Olumiant Up for PAFSC Review for COVID-19 on April 21, Combo Use with Veklury
April 15, 2021
-
BUSINESS Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
April 14, 2021
-
REGULATORY 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
April 14, 2021
-
REGULATORY Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
-
BUSINESS Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
-
BUSINESS Maruho Aspires to Get Back on Growth Track on New Drug Launches: President
April 12, 2021
-
BUSINESS Kobayashi Kako’s Seima Factory Operations Still Halted Even after 60-Day Order Lifted
April 12, 2021
-
ORGANIZATION Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
-
BUSINESS Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
April 9, 2021
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
